{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-076851","form_type":"8-K","ticker":"ANVS","cik":"0001477845","company_name":"Annovis Bio, Inc.","filed_at":"2025-08-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.074425+00:00","generated_at":"2026-05-17T14:25:36.069953+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Annovis Bio Q2 net loss $0.32/sh; cash $17.1M; Phase 3 AD trial advances with 38 patients randomized","bullets":["Cash and cash equivalents $17.1M as of June 30, 2025, up from $10.6M at Dec 31, 2024.","Net loss per share $0.32 (basic/diluted) for Q2 2025 vs $0.44 in Q2 2024.","Phase 3 early AD trial: 38 patients randomized, nearly 200 in screening, 76 U.S. sites (46 enrolling).","R&D expenses $5.2M, G&A $1.1M, both down YoY.","Transferred all patent families to crystal buntanetap, achieving comprehensive global IP coverage."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-076851","json":"https://secwatch.observer/filing/0001104659-25-076851.json","markdown":"https://secwatch.observer/filing/0001104659-25-076851.md","text":"https://secwatch.observer/filing/0001104659-25-076851.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1477845/000110465925076851/0001104659-25-076851-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1477845/000110465925076851/tm2523281d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T14:25:36.069953+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}